Metabolic drug survey highlights cancer cell dependencies and vulnerabilities

Abstract

Metabolic reprogramming contributes to cancer development and progression. Here, the authors show the utility of a metabolic drug library to uncover metabolic vulnerabilities and obtain functional insights into myeloid leukemia biology.